Paid Obesity Clinical Trials
Weight loss clinical trials now enrolling. Access new GLP-1 and combination therapies. Compensation up to $3,000. Studies for adults with BMI 30+ or 27+ with comorbidities.
Compensation
$1,500 - $3,000
Duration
24-68 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-70 years
- BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidity
- Stable body weight (±5%) for at least 3 months
- At least one failed dietary attempt at weight loss
- Willingness to follow study diet and exercise recommendations
- No use of weight loss medications in past 3 months
Who May Not Qualify
- Prior bariatric surgery
- Type 1 diabetes or uncontrolled Type 2 diabetes
- History of pancreatitis
- Personal or family history of medullary thyroid carcinoma
- Current eating disorder diagnosis
Frequently Asked Questions
What obesity treatments are being studied?
+
Current studies include next-generation GLP-1 receptor agonists, dual and triple hormone agonists, and combination therapies. These medications work through various mechanisms to reduce appetite and improve metabolic health.
How much weight loss is expected?
+
Weight loss varies by individual and study drug, but current investigational medications have shown average losses of 15-25% of body weight in clinical trials. Results depend on medication adherence and lifestyle modifications.
Will I receive diet and exercise counseling?
+
Yes, most weight management studies include lifestyle intervention as part of the program, including regular counseling on nutrition and physical activity.
What side effects should I expect?
+
Common side effects of many weight loss medications include nausea, which typically improves over time as doses are gradually increased. The study team monitors for side effects throughout the trial.